Huiping Shuai
12PUBLICATIONS
48CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (12)
Sort by Publication Date:
|Jan 26, 2026
YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice.Jinshan Nan, Huiping Shuai, Jingxin Qiao
|Dec 11, 2025
Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1.Jialu Shi, Xiaoyu Zhao, Xiaohui Jin
|Jul 16, 2025
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.Huiping Shuai, Jingxin Qiao, Chaemin Yoon
|Nov 28, 2024
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.Hin Chu, Huiping Shuai, Jingxin Qiao
|Oct 08, 2024
Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3.Yuanchen Liu, Xiaoyu Zhao, Jialu Shi
|Jun 10, 2023
Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response.Xiaolei Wang, Terrence Tsz-Tai Yuen, Ying Dou
Pageof 2
Frequent Collaborators
12 joint publications
Hin Chu
10 joint publications
Jasper Fuk-Woo Chan
9 joint publications
Jie Zhou
8 joint publications
Kwok-Yung Yuen
6 joint publications
Bingjie Hu
5 joint publications
Jian Lei
5 joint publications
Shengyong Yang
4 joint publications
Xiner Huang
4 joint publications
Shuofeng Yuan
4 joint publications
Jian-Dong Huang
